Search

Displaying results 71 - 80 of 137 in total
  1. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibr...

  2. Drug

    Taprenepag

    go.drugbank.com/drugs/DB12623
    Investigational

    Taprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.

  3. Drug

    Trabodenoson

    go.drugbank.com/drugs/DB13122
    Investigational

    Trabodenoson has been used in trials studying the treatment of Ocular Hypertension (OHT) and Primary Open-Angle Glaucoma (POAG).

  4. Drug

    Povetacicept

    go.drugbank.com/drugs/DB18996
    Investigational

    Povetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).

  5. Drug

    Setogepram

    go.drugbank.com/drugs/DB15447
    Investigational

    Setogepram is under investigation in clinical trial NCT03184584 (Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome).

  6. Drug

    Anecortave

    go.drugbank.com/drugs/DB12081
    Experimental

    Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).

  7. Drug

    NV-5138

    go.drugbank.com/drugs/DB19180
    Investigational

    NV-5138 is under investigation in clinical trial NCT06235905 (Open-label of SPN-820 in Adults With Major Depressive Disorder).

  8. Drug

    YCT-529

    go.drugbank.com/drugs/DB21748
    Investigational

    YCT-529 is under investigation in clinical trial NCT06542237 (Open Label, Repeat Dose Study Evaluating YCT-529 in Healthy Males).

  9. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    [L2933] Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and

  10. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the subli...